MedTech News
.................... by Andrew Celentano
Moving the Needle on Medication Delivery
Drawing on research pioneered at Tufts, Anodyne Nanotech is creating patches that could change the future of medicine
FDA grants 510(k) clearance to Emboliner system for TAVR procedures
The FDA’s decision follows a clinical assessment of the Emboliner, including the PROTECT H2H IDE study.
Johnson & Johnson wins CE mark for new reusable contact lens
Johnson & Johnson MedTech (NYSE: JNJ) announced today that it has received a CE mark for its Acuvue Oasys Max 2-Week, a new reusable contact lens.
Biodegradable drug-delivery nanoparticles curb brain plaque proteins and improve memory in Alzheimer’s mice
A family of nanoparticles—tiny, biodegradable molecules commonly used to deliver drugs to patients—shows promise in treating Alzheimer’s disease without additional medication, according to new research from a University of Alberta neuroscientist.
AI-designed proteins outperform existing CAR T designs against BCMA tumors in mice
CAR T cell therapy, which involves genetically modifying a patient’s own immune cells to fight cancer, is a technique that has shown great promise, especially against blood cancers. But currently, only about 4% of patients with advanced or metastatic cancer in the United States are candidates for CAR T therapy, and closer to 3% will actually benefit, according to one recent analysis.
New imaging method makes fMRI quieter and clearer for brain–behavior research
Functional magnetic resonance imaging, or fMRI, gives researchers a powerful way to study brain activity. But the scans can be incredibly noisy for patients and research subjects, with peak sound levels reaching 120 to 138 decibels—about as loud as a jackhammer.
Wireless brain-recording device enables animal neuroscience experiments in natural habitats
A new wireless device—lighter than a U.S. dime and shaped like a tiny chef’s hat—can track the brain waves of animals as they move in natural habitats, opening doors to understanding complex behaviors that are impossible to study in the lab.
Novel immunotherapy leads to complete regression of chemotherapy-resistant liver cancer in 3-year-old
A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children’s Hospital and Seattle Children’s describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.